Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
High Grade Serous Adenocarcinoma of Ovary: early-phase trial registry
1 of 4 indexed High Grade Serous Adenocarcinoma of Ovary trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
High Grade Serous Adenocarcinoma of Ovary: 4 US clinical trials tracked, 1 recruiting.
High Grade Serous Adenocarcinoma of Ovary is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Volastra Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition high-grade-serous-adenocarcinoma-of-ovary
OPEN 1 | RECR 25% | LATE 0 | EARLY 4 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
High Grade Serous Adenocarcinoma of Ovary lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for High Grade Serous Adenocarcinoma of Ovary on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
High Grade Serous Adenocarcinoma of Ovary is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Volastra Therapeutics
NCT05902988
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
NCT05527184
A Study of Sovilnesib in Subjects With Ovarian Cancer
Volastra Therapeutics
NCT06084416
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
OncoC4
NCT05446298
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on High Grade Serous Adenocarcinoma of Ovary records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on High Grade Serous Adenocarcinoma of Ovary trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this High Grade Serous Adenocarcinoma of Ovary page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 High Grade Serous Adenocarcinoma of Ovary trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Volastra Therapeutics sponsors the most High Grade Serous Adenocarcinoma of Ovary trials on record, review their full trial history before evaluating a specific study. See Volastra Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This High Grade Serous Adenocarcinoma of Ovary condition card totals 4 registered trials; most-linked intervention Sovilnesib; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.